Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 15/20 | 0.39 |
| ▸ | CA2 | P00918 | 15/20 | 0.39 |
| ▸ | CA12 | O43570 | 10/20 | 0.39 |
| ▸ | CA9 | Q16790 | 10/20 | 0.39 |
| ▸ | EPAS1 | Q99814 | 2/20 | 0.37 |
| ▸ | RORC | P51449 | 1/20 | 0.37 |
| ▸ | CA5A | P35218 | 2/20 | 0.35 |
| ▸ | CA7 | P43166 | 2/20 | 0.35 |
| ▸ | CA5B | Q9Y2D0 | 2/20 | 0.35 |
| ▸ | CA13 | Q8N1Q1 | 1/20 | 0.34 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2638578 | 0.95 | CA1 (0.41) | CA1CA2CA12CA9EPAS1 | |
| SCHEMBL2638815 | 0.93 | CA1 (0.41) | CA1CA2CA12CA9EPAS1 | |
| SCHEMBL2638086 | 0.92 | CYP3A4 (0.40) | CA1CA2CA12CA9EPAS1 | |
| SCHEMBL2639162 | 0.92 | CA1 (0.45) | CA1CA2CA12CA9RORC | |
| SCHEMBL2638576 | 0.89 | CA1 (0.40) | CA1CA2CA12CA9EPAS1 | |
| SCHEMBL2638642 | 0.88 | CA1 (0.47) | CA1CA2CA12CA9RORC | |
| SCHEMBL2638984 | 0.86 | CA1 (0.42) | CA1CA2CA12CA9EPAS1 | |
| SCHEMBL2639435 | 0.85 | CYP3A4 (0.44) | CA1CA2CA12CA9CA5A | |
| SCHEMBL2638439 | 0.84 | CA1 (0.49) | CA1CA2CA12CA9RORC | |
| SCHEMBL2638415 | 0.83 | CYP3A4 (0.49) | CA1CA2CA12CA9RORC |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-4833385-B1 | — | — | 2011-12-07 | — | — | JP | claimed |
| JP-4810529-B2 | — | — | 2011-11-09 | — | — | JP | claimed |
| WO-2010041194-A1 | TRICYCLIC OXAZOLIDINONE ANTIBIOTIC COMPOUNDS | ACTELION PHARMACEUTICALS LTD (CH) | 2010-04-15 | — | — | WO | claimed |
| US-7625949-B2 | Methods for treating retroviral infections | ROCHE PALO ALTO LLC (US) | 2009-12-01 | — | — | US | claimed |
| EP-1742908-B1 | NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS | HOFFMANN LA ROCHE (CH) | 2009-11-11 | — | — | EP | claimed |
| US-7166738-B2 | Non-nucleoside reverse transcriptase inhibitors | ROCHE PALO ALTO LLC (US) | 2007-01-23 | — | — | US | claimed |
| EP-1742908-A1 | NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS | F.HOFFMANN-LA ROCHE AG (CH) | 2007-01-17 | — | — | EP | claimed |
| WO-2005102989-A1 | NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2005-11-03 | — | — | WO | claimed |
| US-20050239881-A1 | Non-nucleoside reverse transcriptase inhibitors | ROCHE PALO ALTO LLC | 2005-10-27 | — | — | US | claimed |
| US-20050239880-A1 | Methods for treating retroviral infections | ROCHE PALO ALTO LLC | 2005-10-27 | — | — | US | claimed |
| US-8329755-B2 | Methods for treating retroviral infections | ROCHE PALO ALTO LLC (US) | 2012-12-11 | — | — | US | disclosed |
| WO-2010041194-A1 | TRICYCLIC OXAZOLIDINONE ANTIBIOTIC COMPOUNDS | ACTELION PHARMACEUTICALS LTD (CH) | 2010-04-15 | — | — | WO | disclosed |
| US-20100041648-A1 | METHODS FOR TREATING RETROVIRAL INFECTIONS | DUNN JAMES PATRICK | 2010-02-18 | — | — | US | disclosed |
| US-7625949-B2 | Methods for treating retroviral infections | ROCHE PALO ALTO LLC (US) | 2009-12-01 | — | — | US | disclosed |
| EP-1742908-B1 | NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS | HOFFMANN LA ROCHE (CH) | 2009-11-11 | — | — | EP | disclosed |
| US-7166738-B2 | Non-nucleoside reverse transcriptase inhibitors | ROCHE PALO ALTO LLC (US) | 2007-01-23 | — | — | US | disclosed |
| EP-1742908-A1 | NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS | F.HOFFMANN-LA ROCHE AG (CH) | 2007-01-17 | — | — | EP | disclosed |
| WO-2005102989-A1 | NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2005-11-03 | — | — | WO | disclosed |
| US-20050239881-A1 | Non-nucleoside reverse transcriptase inhibitors | ROCHE PALO ALTO LLC | 2005-10-27 | — | — | US | disclosed |
| US-20050239880-A1 | Methods for treating retroviral infections | ROCHE PALO ALTO LLC | 2005-10-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100041648-A1 | METHODS FOR TREATING RETROVIRAL INFECTIONS | CCR5, CXCR4, CCR1 | CA1 4540/4885CA2 4665/4885CA12 4403/4885 |
| US-20050239880-A1 | Methods for treating retroviral infections | CCR5, CD38, CD4 | CA1 4673/4885CA2 4716/4885CA12 4711/4885 |
| US-20050239881-A1 | Non-nucleoside reverse transcriptase inhibitors | RPP30, PNP, RTF1 | CA1 4809/4885CA2 4789/4885CA12 4875/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.